|
Gene: METTL3 |
Gene summary for METTL3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | METTL3 | Gene ID | 56339 |
Gene name | methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit | |
Gene Alias | IME4 | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86U44 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56339 | METTL3 | C21 | Human | Oral cavity | OSCC | 5.94e-16 | 6.55e-01 | 0.2678 |
56339 | METTL3 | C30 | Human | Oral cavity | OSCC | 1.31e-13 | 7.19e-01 | 0.3055 |
56339 | METTL3 | C43 | Human | Oral cavity | OSCC | 2.60e-19 | 4.55e-01 | 0.1704 |
56339 | METTL3 | C46 | Human | Oral cavity | OSCC | 3.14e-15 | 3.82e-01 | 0.1673 |
56339 | METTL3 | C51 | Human | Oral cavity | OSCC | 2.05e-05 | 4.65e-01 | 0.2674 |
56339 | METTL3 | C57 | Human | Oral cavity | OSCC | 1.61e-02 | 2.55e-01 | 0.1679 |
56339 | METTL3 | C08 | Human | Oral cavity | OSCC | 4.78e-06 | 2.20e-01 | 0.1919 |
56339 | METTL3 | LN46 | Human | Oral cavity | OSCC | 1.82e-02 | 1.89e-01 | 0.1666 |
56339 | METTL3 | LP17 | Human | Oral cavity | LP | 3.76e-02 | 5.19e-01 | 0.2349 |
56339 | METTL3 | SYSMH3 | Human | Oral cavity | OSCC | 9.02e-07 | 3.08e-01 | 0.2442 |
56339 | METTL3 | P4_cSCC | Human | Skin | cSCC | 5.30e-03 | 1.24e-01 | -0.00290000000000005 |
56339 | METTL3 | P10_cSCC | Human | Skin | cSCC | 2.49e-06 | 3.56e-01 | 0.1017 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
METTL3 | SNV | Missense_Mutation | c.1177N>G | p.Met393Val | p.M393V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
METTL3 | SNV | Missense_Mutation | c.1522N>G | p.Arg508Gly | p.R508G | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | deletion | Frame_Shift_Del | novel | c.1626delN | p.Asn543ThrfsTer15 | p.N543Tfs*15 | Q86U44 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
METTL3 | SNV | Missense_Mutation | c.1495N>A | p.Asp499Asn | p.D499N | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
METTL3 | SNV | Missense_Mutation | c.656N>T | p.Ser219Leu | p.S219L | Q86U44 | protein_coding | tolerated(0.1) | benign(0.021) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
METTL3 | SNV | Missense_Mutation | novel | c.52N>G | p.Leu18Val | p.L18V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
METTL3 | SNV | Missense_Mutation | novel | c.341N>G | p.Asp114Gly | p.D114G | Q86U44 | protein_coding | tolerated(0.37) | benign(0) | TCGA-A6-3807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Ancillary | leucovorin | SD |
METTL3 | SNV | Missense_Mutation | c.157C>T | p.Pro53Ser | p.P53S | Q86U44 | protein_coding | tolerated(0.4) | benign(0.019) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | SNV | Missense_Mutation | c.1243N>T | p.Arg415Cys | p.R415C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | SNV | Missense_Mutation | c.1217A>G | p.Tyr406Cys | p.Y406C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3989-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |